Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects.

Abstract

Accurate diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency is required to avoid the risk of acute hemolysis associated with 8-aminoquinoline treatment. The performance of the BinaxNOW G6PD test compared with the quantitative spectrophotometric analysis of G6PD activity was assessed in 356 Plasmodium vivax-infected subjects in Brazil, Peru, Thailand, and India. In the quantitative assay, the median G6PD activity was 8.81 U/g hemoglobin (range = 0.05-20.19), with 11 (3%) subjects identified as deficient. Sensitivity of the BinaxNOW G6PD to detect deficient subjects was 54.5% (6 of 11), and specificity was 100% (345 of 345). Room temperatures inadvertently falling outside the range required to perform the rapid test (18-25°C) together with subtlety of color change and insufficient training could partially explain the low sensitivity found. Ensuring safe use of 8-aminoquinolines depends on additional development of simple, highly sensitive G6PD deficiency diagnostic tests suitable for routine use in malaria-endemic areas.

• Authors: Lyda Osorio, Nick Carter, Preetam Arthur, Germana Bancone, Sowmya Gopalan, Sandeep K Gupta, Harald Noedl, Sanjay K Kochar, Dhanpat K Kochar, Srivicha Krudsood, Marcus V Lacerda, Alejandro Llanos-Cuentas, Ronnatrai Rueangweerayut, Ramadurai Srinivasan, Moritz Treiber, Jörg J Möhrle, Justin Green
• Journal: The American journal of tropical medicine and hygiene (Am J Trop Med Hyg) Vol. 92 Issue 1 Pg. 22-27 (Jan 2015) ISSN: 1476-1645 [Electronic] United States
• PMID: 25385861 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The American Society of Tropical Medicine and Hygiene.

Chemical References

• Antimalarials

Topics

• Antimalarials (therapeutic use)
• Glycogen Storage Disease Type I (diagnosis)
• Humans
• Malaria, Vivax (drug therapy)
• Point-of-Care Systems
• Sensitivity and Specificity